Bausch + Lomb Corporation (NYSE:BLCO; TSX:BLCO), a global eye health company, has been navigating a complex market landscape characterized by both promising opportunities and significant challenges.

In December, Bausch + Lomb announced the acquisition of Elios Vision, a global eye health company that developed the ELIOS procedure. 2 This minimally invasive glaucoma surgery is expected to be used ...

Executives at Bausch Health Cos Inc are shaking up the company’s team of advisers as part of the latest in a years-long ...

Barclays raised the firm’s price target on Bausch + Lomb (BLCO) to $19 from $18 and keeps an Equal Weight rating on the shares. The firm says ...

Stifel Nicolaus analyst Thomas Stephan maintained a Hold rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a price ...

Learn more about whether Bausch + Lomb Corporation or Inari Medical, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

“Surgeons around the world have long known the benefits of the enVista platform,” said Luc Bonnefoy, president, Surgical, Bausch + Lomb. “In the U.S., where enVista Aspire is currently ...

Bausch + Lomb launched the enVista Aspire monofocal and toric IOLs in the European Union, according to a press release.Using intermediate optimized optics, the lenses offer a range of vision beyond ...

VAUGHAN, Ontario, January 13, 2025--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today ...

VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX ... for treatment of their astigmatism during cataract surgery. Featuring a +0.90 cylinder design, the enVista toric ...